Methods of treating ulcerative colitis
AssigneeMillennium Pharmaceuticals, Inc.
InventorsIrving H. Fox, Catherine Scholz
Life of this patent
Estimating the term…
Abstract
Methods for maintaining clinical remission of ulcerative colitis in a human patient are described comprising administration of an antibody that has binding specificity for human alpha4beta7 integrin using a safe dosing regimen of these antibody formulations that is easy to follow, and which results in a therapeutically effective amount of the anti-alpha4beta7 antibody in vivo.
Claims12
A method for treating a human patient suffering from ulcerative colitis, wherein the method comprises the steps of:
- administering to a patient suffering from ulcerative colitis, an initial 300 mg dose of a humanized antibody having binding specificity for human alpha4beta7 integrin,
- administering a second subsequent dose of 300 mg of the humanized antibody two weeks after the initial dose;
- administering a third subsequent dose of 300 mg of the humanized antibody six weeks after the initial dose;
- and
- administering subsequent doses of 300 mg of the humanized antibody every four weeks or every eight weeks after the third subsequent dose of the humanized antibody as needed;
- wherein the humanized antibody comprises light chain CDRs as set forth in SEQ ID NO:
- 11 (CDR1), SEQ ID NO:
- 12 (CDR2), and SEQ ID NO:
- 13 (CDR3), and comprises heavy chain CDRs as set forth in SEQ ID NO:
- 8 (CDR1), SEQ ID NO:
- 9 (CDR2), and SEQ ID NO:
- 10 (CDR3).
A method for treating a human patient suffering from ulcerative colitis, wherein the method comprises the steps of:
- administering to a patient suffering from ulcerative colitis, an initial 300 mg dose of vedolizumab,
- administering a second subsequent dose of 300 mg of vedolizumab two weeks after the initial dose;
- administering a third subsequent dose of 300 mg of vedolizumab six weeks after the initial dose;
- and
- administering subsequent doses of 300 mg of vedolizumab every four weeks or every eight weeks after the third subsequent dose.
Dependencies are inferred from the claim text.